Overview

A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study in COPD patients will investigate the bronchodilatory effect of AZD2115. AZD2115 will be tested versus placebo and active comparators. The safety and tolerability of AZD2115 including investigations of clinically relevant systemically mediated effects will also be investigated.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Tiotropium Bromide